Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8723429 | Médecine des Maladies Métaboliques | 2018 | 5 Pages |
Abstract
During the recent international meetings, were reported several trials evaluating the cardiovascular effects of the GLP-1 receptor agonists (GLP1-RA). Here we analyze and criticize the drug-agencies-required methodology used in these studies, which did not lead to equipoise between the arms with regard to risk factors. However, by taking together all these studies, we can conclude that GLP1-RA, when used at their maximal doses, are potent tools in secondary cardiovascular prevention, through leveraging on control of blood glucose and blood pressure.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
R. Roussel, A. Bumbu,